Amneal Pharmaceuticals
440 U.S. Highway 22 East
Suite 104
Bridgewater
New Jersey
08807
United States
Tel: 908-947-3120
Fax: 908-947-4146
Website: http://www.amneal.com/
275 articles about Amneal Pharmaceuticals
-
Amneal to Report Third Quarter 2019 Results on November 6, 2019
10/9/2019
The Company will host a conference call and live webcast with the investment community at 8:30 a.m., Eastern Time on November 6, 2019.
-
BioSpace scanned the WARN (Worker Adjustment and Retraining Notification) notices across the country and compiled a small list of recent layoffs across the industry.
-
MedicaSafe Announces Partnership with Amneal Pharmaceuticals
10/3/2019
MedicaSafe will combine the generic version of Suboxone® (buprenorphine and naloxone) with its smart medication systems to treat opioid dependence
-
Amneal Announces Approval of Generic Version of Amicar®
9/5/2019
Amneal Pharmaceuticals, Inc. (NYSE: AMRX), today announced that it has received approval from the U.S. Food and Drug Administration (FDA) for its generic version of Amicar® (aminocaproic acid oral solution) 0.25g/mL.
-
Amneal Pharmaceuticals to Present at the Morgan Stanley 17th Annual Global Healthcare Conference
9/3/2019
Morgan Stanley 17th Annual Global Healthcare Conference in New York on Tuesday, September 10, 2019 at 2:55 p.m. Eastern Time.
-
Amneal Reports Second Quarter 2019 Financial Results
8/5/2019
Amneal Pharmaceuticals, Inc. announced its results for the second quarter ended June 30, 2019.
-
Amneal Pharmaceuticals Co-Founders Chirag Patel and Chintu Patel Return as Co-Chief Executive Officers
8/5/2019
Amneal Pharmaceuticals, Inc. announced that its Co-Founders, Chirag Patel and Chintu Patel, have been named Co-Chief Executive Officers, effective immediately.
-
Alkermes Announces Settlement With Amneal Over VIVITROL® Patent Dispute
7/29/2019
Patent Trial and Appeal Board Oral Hearing Cancelled
-
Amneal Announces Launch of Generic Lyrica®
7/22/2019
Amneal Pharmaceuticals, Inc., announced that it has received approval for, and launched, its generic version of Lyrica® (pregabalin capsules) 25 mg, 50 mg, 75, mg, 100 mg, 150 mg, 200 mg, 225 mg and 300 mg.
-
The drug is approved for use for management of neuropathic pain associated with diabetic peripheral neuropathy, postherpetic neuralgia, adjunctive therapy for partial-onset seizures in patients 17 years of age and older, fibromyalgia, and neuropathic pain associated with spinal cord injury.
-
More than 600 employees will lose their jobs as the companies reshape their corporate strategies.
-
Amneal Pharmaceuticals Announces Restructuring and Costs Savings Plan to Improve Operations and Position the Company for Future Growth
7/10/2019
Amneal Pharmaceuticals, Inc. announced a comprehensive restructuring plan designed to reduce its cost base, further right size its organization and optimize its global manufacturing infrastructure.
-
Amneal did not specify any layoffs as part of the cut, but did note that employees affected by the decision will be provided comprehensive transition plan.
-
Amneal to Report Second Quarter 2019 Results on August 8, 2019
7/9/2019
Amneal Pharmaceuticals, Inc. will release its second quarter 2019 financial results on Thursday, August 8, 2019, prior to the open of the U.S. financial markets.
-
AMNEAL INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Amneal Pharmaceuticals, Inc. - AMRX - June 14, 2019
6/14/2019
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC ("KSF"), announces that KSF has commenced an investigation into Amneal Pharmaceuticals, Inc. (NYSE: AMRX).
-
Amneal Pharmaceuticals to Present at Upcoming Investor Conferences - June 6, 2019
6/6/2019
Amneal Pharmaceuticals, Inc. announced that members of management will participate at the following upcoming investor conferences
-
AMNEAL INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Amneal Pharmaceuticals, Inc. - AMRX
5/18/2019
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Amneal Pharmaceuticals, Inc. (NYSE: AMRX).
-
Amneal Pharmaceuticals to Present at the RBC Capital Markets Global Healthcare Conference
5/15/2019
Amneal Pharmaceuticals, Inc. (NYSE:AMRX) today announced that members of management will participate in a fireside chat at the RBC Capital Markets Global Healthcare Conference in New York on Tuesday, May 21, 2019 at 11:00 a.m. Eastern Time.
-
AMNEAL INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Amneal Pharmaceuticals, Inc. To Contact The Firm
5/13/2019
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Amneal Pharmaceuticals, Inc..
-
Amneal Reports First Quarter 2019 Financial Results
5/9/2019
Amneal Pharmaceuticals, Inc. announced its results today for the first quarter ended March 31, 2019.